Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.